iTeos Therapeutics downgraded by Wedbush with a new price target
$ITOS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Wedbush downgraded iTeos Therapeutics from Outperform to Neutral and set a new price target of $12.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $12.00 | Overweight → Equal Weight | Wells Fargo |
| 5/28/2025 | $12.00 | Outperform → Neutral | Wedbush |
| 5/14/2025 | $9.00 | Outperform → Market Perform | Leerink Partners |
| 5/14/2025 | Buy → Neutral | H.C. Wainwright | |
| 5/13/2025 | Overweight → Neutral | Analyst | |
| 8/13/2024 | $31.00 | Overweight | Wells Fargo |
| 12/13/2021 | $37.00 → $54.00 | Buy | HC Wainwright & Co. |
| 11/12/2021 | $55.00 → $54.00 | Outperform | SVB Leerink |